Foghorn Therapeutics (FHTX) Stock Rating Cut by Wedbush
Published on Β· Source: investing.com
AI Summary
Summarized by AI from the source belowWedbush downgraded Foghorn Therapeutics (FHTX) following a setback related to its drug development. The specific reasons for the downgrade were not disclosed in the article. This change in rating could signify potential challenges for the company in meeting market expectations and raise concerns among investors. The announcement highlights the need for investors to stay informed about developments that may affect Foghorn's performance in the market.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Understand this kind of story
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Related News
Liquidia (LQDA) Stock Price Target Cut to $58 on Patent Uncertainty
Oct 2
Nektar Therapeutics (NKTR) Stock Rating Reiterated on Alopecia Data
Oct 2
Foghorn Therapeutics (FHTX) Price Target Cut to $5 After Program Halt
Oct 2
Northland Begins Coverage on WW International (WW) with Outperform Rating
Oct 2